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We achieved possibility of isolation, characterization human umbilical cord blood endothelial
progenitor cells (EPCs), examination potency of EPCs to form new blood vessels and differen-
tiation into cardiomyoctes in canines with acute myocardial infarction (AMI). EPCs were sep-
arated and cultured from umbilical cord blood. Their phenotypes were conﬁrmed by uptake of
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Acute myocardial infarctiondouble stains dioctadecyl tetramethylindocarbocyanine-labeled acetylated LDL and FITC-
labeled Ulex europaeus agglutinin 1 (DILDL-UEA-1). EPCs of cord blood were counted.
Human VEGFR-2 and eNOS from the cultured EPCs were assessed by qPCR. Human EPCs
was transplanted intramyocardially in canines with AMI. ECG and cardiac enzymes
(CK-MB and Troponin I) were measured to assess severity of cellular damage. Histopathology
was done to assess neovascularisation. Immunostaining was done to detect EPCs transdifferen-
tiation into cardiomyocytes in peri-infarct cardiac tissue. qPCR for human genes (hVEGFR-2,
and eNOS) was done to assess homing and angiogenic function of transplanted EPCs. Cultured
human cord blood exhibited an increased number of EPCs and signiﬁcant high expression of
hVEGFR-2 and eNOS genes in the culture cells. Histopathology showed increased neovascular-
ization and immunostaining showed presence of EPCs newly differentiated into cardiomyocyte-
like cells. Our ﬁndings suggested that hEPCs can mediate angiogenesis and differentiate into
cardiomyoctes in canines with AMI.
ª 2014 Production and hosting by Elsevier B.V. on behalf of Cairo University.Introduction
Chronic total occlusion (CTO) is diagnosed in patients with
coronary artery disease during angiography [1]. Multivessel
disease (MVD) effects are due to the presence of CTO in a
noninfarct-related artery [2]. CTO lesion in a non-infarct re-
lated artery was a high risk factor for mortality after acute
myocardial infarction (AMI) [3].
Endothelial progenitor cells (EPCs), described as a hetero-
geneous population of circulating cells in peripheral blood [4].
Their origin is found in multiple precursors, such as hemangio-
blasts, non-hematopoietic precursors, monocytic cells, or tis-
sue-resident stem cells. EPCs play an important role in
vasculogenesis because of their capacity to proliferate, migrate,
differentiate in vivo and in vitro into endothelial cells, and
incorporate into the preexisting endothelium. Thus, phenotyp-
ically, they have morphofunctional characteristics of both
hematopoietic and mature endothelial cells [5]. EPCs are rare,
representing approximately 0.01%–0.0001% of the mononu-
clear fraction in peripheral blood. However, several stimuli,
such as physical exercise, can mobilize them from bone mar-
row, temporarily increasing their number in peripheral circula-
tion. EPCs neovasculogenesis function was due to secretion of
pro-angiogenic factors such as vascular endothelial growth
factor (VEGF) and granulocyte colony stimulating factor
(G-CSF) [6]. Early EPCs (present in the BM or directly after
reaching the bloodstream) are CD133+/CD34+/VEGFR2+
cells, whereas circulating EPCs are CD34+ and VEGFR-2+,
CD133 and start to express membrane molecules typical to
mature ECs [7].
Experimental studies revealed that intravascular or intra-
myocardial administration of EPCs may enhance functional
regeneration of infracted myocardium and neovascularization
of ischemic myocardium [8]. Clinical studies suggested that
intracoronary infusion of progenitor cells is accessible and
may greatly affect left ventricular contractile function or de-
crease infarct size in patients with AMI. Previous results either
experimental or clinical provide important evidence about use
of progenitor cell in cell therapy of chronic coronary artery
disease [9].
Studies showed an increase in capillary density associated
with an improvement of ventricular function and a reduction
in ventricular size three months after stem cell transplantation
into the under perfused myocardial segments compared to
control group [10,11]. These effects could be increased by
preincubation of the stem cells with cardiomyogenic growthfactors leading to a cardiomyogenic differentiation. Applying
these modiﬁed stem cells in an infraction model; an improved
functional recovery was obvious when compared with the
transplantation of unmodiﬁed stem cells [12]. EPCs in healthy
individuals may be a biologic marker for vascular function.
Moreover, low levels of circulating EPCs may predict early
atherosclerosis, occurrence of cardiovascular disorders, death
from cardiovascular disorders [13] and prognosis after ische-
mic stroke [14]. The previous ﬁnding indicates that EPCs play
an important part in the pathogenesis of atherosclerotic dis-
ease and assessment of EPCs may improve risk of cardiovascu-
lar disorders. This study aimed to prove that human EPCs can
differentiate into cardiac myocytes after intramyocadial trans-
plantation into canine with AMI. Phenotypic and functional
biomarkers were assessed to prove myocardial differentiation.
Methodology
EPCs isolation from human umbilical cord blood
Five samples of human cord blood were enrolled in our after
taken informed consents from women during caesarean sections
labor. All procedures followed were in accordance with the ethi-
cal standards of the responsible committee on human experimen-
tation (institutional and national) and with the Helsinki
Declaration of 1975, as revised in 2008. The blood mononuclear
cell fraction (MNCs) was isolated from the buffy coats
through density-gradient centrifugation with 20 ml Ficoll-Pa-
que (Gibco-Invitrogen, Grand Island, NY). Centrifugation
was for 35 min at 400g. The interphase layer of MNC was
carefully aspirated and washed in PBS containing 2 mM
EDTA and further centrifuged for 10 min at 200g. The cell
pellet was resuspended in 300 ll buffer and cultured for further
cells propagation.
EPCs culture, propagation, labeling and counting based assay
EPCs were identiﬁed in culture by formation of a Colony
Forming Unit (CFU) [5]. CFUs were formed after MNCs
culturing for 7 days. For the EPCs counting assay, 5 · 106
MNCs were cultured onto ﬁbronectin coated 96-well plates
in M199 medium supplemented with 20% fetal calf serum
(FCS), 0.1% human vascular endothelial growth factor-1
(VEGF-1) and 0.1% insulin-like growth factor (IGF-1) at
37 C for 48 h. After seven days, EPCs were stained and further
labeled with 1,10-dioctadecyl-3,3,30,30-tetramethylindocarbocya-
Human EPCs and angiogenesis 135nine-labeled acetylated LDL (DiLDL,) and FITC-labeled Ulex
europaeus agglutinin 1 (UEA-1, Sigma Chemical Company)
Lectin. This double staining is speciﬁc for EPCs identiﬁcation.
EPCs were counterstained with 40,6-diamidino-phenylindole
(DAPI) for 10 min and visualized as a distinct blue cytoplasm
under inverted ﬂuorescent microscope (Lieca, Germany).
DAPI staining was to ensure cells viability. Only double
stained cells (DILDL-FITC labeled UEA-1) with a distinctly
blue cytoplasm (DAPI positive cells) were counted in a ﬁve
random ﬁelds [15].
EPCs function assessment
Total RNA was isolated from collected cultured human EPCs
using Qiagene cells/tissue extraction kit (Qiagene, USA)
according to instructions of manufacture. The purity (A260/
A280 ratio) and the concentration of RNA were obtained
using spectrophotometry (dual wave length Beckman, Spectro-
photometer, USA). The extracted and puriﬁed RNA samples
were subjected to RNase inhibitor at 37 C for 20 min and
stored at –80 C for further use.
Two lg RNA was reversed into cDNA using high capacity
cDNA reverse transcription kit (#K1621, Fermentas, USA).
The cDNA 25 ll master mix was prepared; ﬁrst strand buffer
(10·) 5 ll, 10 mM dNTP’s, RNase inhibitor (40 U/ll),
MMLV-RT enzyme (50 U/ll), and DEPC-treated water. RT
mix was incubated for one hour at 37 C followed by inactiva-
tion of enzymes at 95 C for 10 min, and cooled at 4 C. qPCR
was performed using an Applied Biosystem with software ver-
sion 3.1 (StepOne, USA). cDNA including previously pre-
pared samples (for VEGFR-2 and eNOS genes expression),
internal control (for GAPDH gene expression as housekeeping
gene), and non-template control (to assure absence of DNA
contamination), were in duplicate. Each 25 lL of reaction
mix contained 12.5 lL of SYBR Green (Fermentas), 1 lL of
each primers (10 lmol/L), and cDNA (1 lg/mL) for sample
determination. The thermal reaction was initiated by activa-
tion of Taq polymerase at 95 C for 5 min, followed by 40
ampliﬁcation cycles: 10 s denaturizing at 95 C, 50 s annealing
at 59 C (VEGF-R2) or 61.2 C (eNOS). After the RT-PCR
run the data were expressed in Cycle threshold (Ct) of assessed
genes (VEGFR-2 and eNOS) and the house keeping gene
(GAPDH). Therefore, Relative quantitation (RQ) of target
genes expression was assessed and related to housekeeping
gene by previously published method RQ= 2(DDCt) [16,17].
Sequence of primers was designed as in Table 1.
Induction of experimental AMI model
The study comprised 12 mongrels canines, aged from 1–2 years
and weighed between 17–26 kg. All Institutional and National
Guidelines for the care and use of animals were followed. Dogs
were subjected to anesthesia with ketamine (10 mg/kg IV)Table 1 Shows the primers sequence for the VEGF-R2&eNOS gen
Gene Forward primer
VEGF-R2 GATGTGGTTCTGAGTCCGTCT
eNOS ATTATATCCTACACAAGACTCCAG
GAPDH CCTCTACTGGCGCTGCCAAGGCTand diazepam (1 mg/kg IV). After intubation, anesthesia was
maintained with all dogs, AMI was performed by left thoraco-
tomy followed by ligation of the left anterior descending coro-
nary artery (LAD) distal to the ﬁrst diagonal branch (Fig. 1).
Experimental animals were two groups: group 1: EPCs-AMI
treated canines were subjected to intramyocardial transplanta-
tion of pooled EPCs (5 · 106 cells/2 ml infusion saline) isolated
from 5 human umbilical cord blood samples (Fig. 2) and group
2: AMI canines were subjected to 2 ml intramyocardial saline
injection as control placebo group.
Assessment and follow up
Vital signs (blood pressure, heart rate, temperature and O2 sat-
uration) as well as laboratory tests (blood count to assess
inﬂammatory response, troponin I and creatin kinase-MB
fraction to assess myocardial damage) were obtained one day
after LAD ligation, seven and 26 ± 4 days after cell/placebo
infusion. Cardiac noninvasive monitoring, including lead II
electrocardiograms (ECGs) was recorded before and at various
time intervals after cell infusion.Animal scariﬁcation
At 26 ± 4 days after cell or placebo infusion, the animals were
sacriﬁced with euthanasia. The hearts were dissected after
median sternotomy. After gross examination, the hearts were
divided into two parts:
One part was ﬁxed in 10% formaldehyde for 48 h for par-
afﬁn embedding. Some ﬁxed sections (5 lm) were further
stained with hematoxylin and eosin for qualitative histopathol-
ogical analysis speciﬁcally targeted to assess for scar tissue,
new blood vessels development, inﬂammation and/or infarc-
tion lesions. Other parafﬁn sections were stained with Tri-
chrome to evaluate ﬁbrosis and collagen deposition. Further
sections were cryosectioned and remained unstained for ﬂuo-
rescence examination of labeled EPCs, to assess homing, trans-
differentiation and tracing of transplanted cells.Immunostaining for detection of EPCs differentiation
The survival of engrafted cells was identiﬁed by labeled DiL-
DL- and DAPI-positive cells in frozen unstained sections
made from the heart tissues. Differentiation to cardiac-like
cells from injected EPCs was identiﬁed by antibody immuno-
staining for cardiac troponin I. Brieﬂy, frozen cutting un-
stained tissue sections were ﬁxed in acetone at 4 C for
10 min and further incubated with a goat polyclonal immuno-
globulin G anti-troponin I antibody (Santa Cruz Biotechnol-
ogy, Inc.) for 60 min at room temperature. Sections were
washed in PBS solutions and incubated with a biotinylated
secondary antibody and streptavidin-FITC (both Vectores.
Reverse primer Accession number
CATGGCTCTGCTTCTCCTTTG NT_022853.15
TCTTCAAGTTGCCCATGTTAC NT_007914.15
GTCCACCACTGACACGTTGG NT_009759.16
Fig. 1 This ﬁgure represents the steps of LAD ligation operation: (A) thoracotomy, (B) Opening of the pericardium, (C) Lifting of LAD,
(D) Ligation and suturing of LAD, (E) Closure of pericardium, (F) Closure of thorax.
Fig. 2 This ﬁgure represents steps of the second operation, (A) one week after LAD ligation: myocardial infarction (B) injection of EPCs
(group 1) or saline (group 2) in the peri-infarct area one week after LAD ligation.
136 M.T. Abd El Aziz et al.Laboratories) immunoglobulin G for troponin I. Human
endothelial cells differentiated to cardiac like cells were
identiﬁed with a phycoerythrin-conjugated anti-human
HLA-DR antibody (Caltag) [18].Homing assessment of transplanted EPCs
The other part of heart was further processed for RNA extrac-
tion followed by RT (for cDNA synthesis) and qPCR for
human VEGF-R2 and eNOS. qPCR for these expressed genes
to assess homing of cells and estimate their function in neovas-
ularization and cardiac repair in peri-infarct cardiac tissue [19].
The same steps as described previously at the in vitro part for
RNA isolation from EPCs followed by real time PCR using
SYBER Green I.Statistical analysis
The data were presented as mean ± SD. Computerized data
were analyzed using SPSS 15.0 software (SPSS Inc.). ANOVA
was used to determine signiﬁcant differences between differentgroups. Signiﬁcant differences were considered when P
value < 0.05.
Results
EPCs isolation, culture, and propagation
EPCs in culture
Human umbilical cord blood EPCs were isolated, cultured and
propagated for 7 days on ﬁbronectin coated wells using media
supplemented with speciﬁc growth factors as; VEGF-1 and
IGF-1 (Fig. 3a and b). They were rounded in shapes and ad-
here to ﬁbronectin plates.
EPCs-CFU characterization in culture
EPCs were characterized in culture by formation of CFU
(Fig. 3c and d). CFU was identiﬁed as a central rounded cells
surrounded by elongated spindled-shaped cells.
EPCs characterization by speciﬁc ﬂuorescent stains
EPCs were characterized by their speciﬁc double ﬂuorescent
staining with DiLDL-UEA-1 stains (Fig. 4a–c). EPCs stained
Fig. 3 (A) EPCs at 0 day of culture, EPCs were rounded in their shape and adherent on ﬁbronectin plate. (B) EPCs were more conﬂuent
in culture on 4th day (200· magniﬁcation). (C) EPCs-CFU at 24 h cultured on ﬁbronectin plate and was as central core of rounded cells
surrounded by elongated spindled-shaped cells (200· magniﬁcation). (D) at 7 days of culture more conﬂuent (400· magniﬁcation).
Fig. 4 This ﬁgure represents picture for speciﬁc DiLDL-UEA-1 double staining of EPCs in culture for characterization. (A) DiLDL
staining (200· magniﬁcation) and (B) UEA-1 staining (200· magniﬁcation). (C) merged picture for DiLDL-UEA-1 double staining of
EPCs (200· magniﬁcation).
Fig. 5 This ﬁgure represents picture for characterization of
viability of cultured EPCs by positive-DAPI blue cytoplasm
staining (200· magniﬁcation).
Human EPCs and angiogenesis 137with DAPI to ensure their viability and survival in vitro
(Fig. 5).
EPCs counting and functions
EPCs were signiﬁcantly higher as regarding count and function
at early (2 days) and late (7 days) times of culture as shown in
Table 2.
Results
Biochemical analysis of troponin I and CK-MB
24 h. after LAD ligation, CK-MB & Troponin I levels showed
marked elevation indicating occurrence of myocardial
Table 2 h EPCs counting & function in relation to time of culture.
Parameter hEPCs at 2 days culture hEPCs at 7 days culture P-value
EPCsX106 count/mL 1.17(3.1) 2.45 (1.9) 0.06
eNOS gene expression 6.4(5.1) 7.1 (2.3) 0.1
VEGF-R2 gene expression 4.2(4.4) 5.65(2.2) 0.04*
Data were expressed as median (range), comparison between early and late cultures was done by paired sample Wilcoxon signed rank test.
* P value <0.05 was signiﬁcant.
Table 3 CK-MB &Troponin I levels in EPCs-AMI treated canines in relation to time after ligation.
EPCs-AMI treated canines (n= 6) CK-MB U/L Troponin ng/ml
After ligation(24 h) 60(16) 0.41(0.15)
After injection (1 week after ligation) 39(5)* 0.19(0.05)*
At scariﬁcation (26 ± 4 days) 31(3)* 0.14(0.02)*
Data were expressed as median (range), comparison was done by paired sample Wilcoxon signed rank test.
* Statistically signiﬁcantly different from (after ligation). P-value < 0.05
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week after intramyocardial infusion and at scariﬁcation,
showed residing of their levels at Table 3.
Electrocardiogram tracings at the indicated time intervals after
intramyocardial infusion of the EPCs
ECG revealed ST segment elevation after 24 h of AMI which
was resolved after one week of EPCs transplantation (Fig. 6).
EPCs homing
Fluorescent cardiac tissue analysis of group II canine showed
no ﬂuorescence indicating no cells transplantation (Fig. 7A).
Di-labeled EPCs transplanted to cardiac tissues of canine withFig. 6 Electrocardiogram tracings before and aLAD were identiﬁed as ﬂuorescent collected cells between stri-
ated cardiac muscles (Fig. 7B). The survival of EPCs was ob-
served as positive-DAPI cells as shown in Fig. 8).
Immunostaining for detection of EPCs differentiation
Transplanted EPCs were differentiated into cardiomyocyte-
like cells and were observed within the ﬁbrotic area of the
infarction and identiﬁed by staining with a speciﬁc cardiac
marker as troponine I (Fig. 9A and B).
Heart histopathological examination
The neighboring non-infracted cardiac tissue in both groups I
and II showed normal striated musculature, stained either withfter intramyocardial infusion of the hEPCs.
Fig. 7 Confocal microscopy showed Fluorescent cardiac tissue analysis. (A) In vivo control for cardiac tissues of group II canine with no
ﬂuorescence of hEPCs. (B) Arrows showed in vivo localization of injected Di-labeled hEPCs for cells tracing and probably developed
neovascularization between striated cardiac muscle tissues. (Magniﬁcation 200·).
Fig. 8 Confocal microscopy shows (A) homing and localization of injected Di-labeled hEPCs within cardiac striated muscles of canine.
(B) positive-DAPI staining of injected EPCs to document their viability after transplantation (100· magniﬁcation).
Fig. 9 Confocal microscopy image (A) showed transdifferentiation of injected hEPCs into cardiomyocyte-like cells and their green
staining for troponin I as a cardiac marker. (B) showed another view angle to document the localization of differentiated injected hEPCs
stained with troponinI cardiac marker between cardiac striations (magniﬁcation 100·).
Human EPCs and angiogenesis 139HE and MT as shown in Fig. 10. Pathological changes in
infracted cardiac muscle were observed as following: (i) Myo-
cyte necrosis in the form of empty cells (sarcolysis) and esosin-
ophilic granular necrosis with loss of central nuclei. (ii)
Atrophy of myocytes surrounding necrotic zones. (iii) Granu-
lation tissue rich in ﬁbroblasts & inﬂammatory cells (macro-
phages more than lymphocytes & few polymorph nuclear
leucocytes). (iv) Congestion of blood vessels, hemorrhage in
infarction area and nearby intramuscular zones. (v) Fibrous
tissue is loose and edematous (Fig. 11). Pathological changes
in infracted cardiac muscle transplanted with EPCs; in
addition to previous changes observed in acute MI group, the
following changes were added: (i) Many congested capillaries,
congested large blood vessels with budding & branchingindicating neovascularization of area (Fig. 12A). (ii) Fibrosis
was enhanced & denser than in control Fig. 12B) (iii) Collec-
tions of dark oval small cells slightly larger than lymphocytes
in a perivascular localization suggested as EPCs collections
(Figs. 13 and 14).
QRT-PCR gene expression of human VEGF-R2 and eNOS
(after animal scariﬁcation) to assess homing and functional
neovascularisation in canine heart tissues
There is high signiﬁcant difference between VEGFR-2 and
eNOS genes expression on infractioned tissues & VEGFR-2
and eNOS genes expression on adjacent tissues in group 1;
EPCs-AMI treated canines at Table 4. This indicates homing
Fig. 10 Showed normal striated cardiac musculature; (A) stained with HE with 100· magniﬁcation, (B) stained with HE with 1000·
magniﬁcation and arrow showed preserved nuclei, and (C) stained with MT with 100· magniﬁcation.
Fig. 11 Showed infarction cardiac muscle; (A) stained with MT with 200· magniﬁcation and arrow showed ﬁbrous tissue, edema &
inﬂammatory cells, (B) stained with HE with 1000· magniﬁcation and arrow showed eosinophylic necrosis with loss of nuclei and (C)
stained with MT with 200· magniﬁcation and arrow showed congested vessel, RBCs & edema.
Fig. 12 Showed infarction cardiac muscle transplanted with human EPCs; (A) cardiac tissue stained with HE and arrow indicates
collection of large vessels & many budding capillaries within ﬁbrosed infarction (magniﬁcation 200·). (B) cardiac tissue stained with MT
and arrow indicates dense ﬁbrosis with many newly formed capillaries surrounding necrotic muscle (magniﬁcation 200·).
140 M.T. Abd El Aziz et al.and localization of transplanted EPCS and may indicate car-
diac repair.
Human VEGFR-2 and eNOS genes expressions were not
expressed by QRT-PCR in group 2 canine heart tissues as they
were not injected with human EPCs.
Discussion
The objective of the present study aimed isolation and charac-
terization of EPCs from human umbilical cord blood and
examination the role of EPCs in neovascularization and
cardiac regeneration by intramyocardial transplantation ofhuman EPCs in an experimental model (canines) with AMI.
We reported here careful characterization of the investigated
cell population. Our results were agreed with other reports
[20]. The cultured MNCs on ﬁbronectin coated plates with
endothelium based medium were double-positive for DIL-
DL-UEA-1 uptake and lectin binding. FACS data revealed
that about 30% of isolated and cultured MNCs can be ana-
lyzed as EPCs, in accordance with other published data [21].
To exclude that these cells are attached monocytes or macro-
phages, which are also capable for LDL uptake and lectin
binding [22] further identiﬁcation was necessary. The cultured
cells were analyzed and quantiﬁed by RT-PCR and they
Fig. 13 Showed infarction cardiac muscle transplanted with human EPCs; (A) cardiac tissue stained with HE and arrow indicates
neovascularization & branched congested blood vessels within ﬁbrosed infarction (magniﬁcation 10·). (B) cardiac tissue stained with MT
and arrow indicates congestion, hemorrhages & increased intramuscular vessels (magniﬁcation 100·). (C) Dil-labeled human EPCs within
cardiac tissue of canine were branching into newly formed blood vessel.
Fig. 14 Showed infarction cardiac muscle transplanted with human EPCs; (A) cardiac tissue stained with HE and arrow indicates EPCs
collection within ﬁbrosed infarction (magniﬁcation 10·). (B) cardiac tissue stained with HE and arrow indicates EPCs collection
(magniﬁcation 1000·). (C) cardiac tissue stained with MT and arrow indicates EPCs collection (magniﬁcation 1000·). (D) DiLDL-UEA-
1-labeled human EPCs collection within cardiac tissue of canine was branching into newly formed blood vessel.
Table 4 Comparison of gene expressions between infracted
tissues and adjacent normal tissues in EPCs-AMI treated
canines (n= 6).
Median(range)
VEGFR-2 gene expression on adjacent tissues 0.19 (0.019)
VEGFR-2 gene expression on infracted tissues 0.26 (0.043)*
eNOS gene expression on adjacent tissues 0.113 (0.02)
eNOS gene expression on infracted tissues 0.175 (0.025)*
Data were expressed as median (range), comparison was done by
paired sample Wilcoxon signed rank test.
* Statistically signiﬁcantly different from adjacent normal tissues.
P-value < 0.05
Human EPCs and angiogenesis 141exhibited an endothelial phenotype, positive gene expression of
VEGFR-2 and eNOS.
In our present study we found that EPCs at 7 days culture
have a signiﬁcance high number of endothelial precursor cells,
and increase in the quantitative gene expression of VEGFR-2
and eNOS expressed by endothelial precursor cells compared
to those with EPCs at 2 days of culture. These ﬁndings agreed
with several studies as Matsuo et al. [15] who demonstrated
that EPCs from subjects with good collateral formation had
lower rates of in vitro senescence, and more CFUs compared
to those with poor collateral formation. These results indicate
that EPC-mediated angiogenesis might be related to coronarycollateral development to some degree even in humans. In an-
other recent study, Tokgo¨zog˘lu et al. [23] showed that number
of the circulating EPCs were higher among patients with nor-
mal coronary vessels compared to patients with CAD for
CD133+/34+ and CD34+/KDR+ cells. In contrast, Gu¨ven
et al. [24] revealed that the number of EPCs was more among
patients with signiﬁcant CAD especially in those requiring cor-
onary intervention, and EPC numbers correlated with the
angiographic stenosis severity. The controversy between these
two studies might be attributable to the degree of ischemia as
more severe ischemia required intervention could be responsi-
ble for EPC mobilization.
There are several potential explanations for the association
between low EPCs counts and severity of CAD. First was the
presence of other cardiac risk factors. Several studies have
identiﬁed an inverse relation between EPCs counts and cardiac
risk factors. Second explanation was that both low EPCs and
sever CAD were associated with older age. We can say that
harmful processes that contribute to atherosclerosis (diabetes,
aging, inﬂammation, etc.) can also suppress bone marrow
production of EPCs, without any relationship between EPCs
levels and CAD. It may be hypothesized that EPCs counts
decreased with age, and that low EPCs and atherosclerosis
coexist in the elderly without cause and effect relationship [25].
As regards the quantitative values of genes expression by
Real-time PCR and analysis, we found that there was a signif-
icant elevation of eNOS gene expression & VEGFR-2 (KDR)
142 M.T. Abd El Aziz et al.gene expression in good collateral group of patients as com-
pared to poor collateral group of patients. Murohara et al.
[26] identiﬁed that cell clusters, spindle-shaped and cord-like
structures could develop from cultures of CB MNCs. These
cells have property incorporation of acetylated-LDL, released
nitric oxide and expressed VEGFR-2, VE-cadherin, CD31 and
vWF but not CD45. Locally transplanted cells had multiple
endothelial phenotypes, survived and participated in capillary
networks in the ischemic tissues of immunodeﬁcient nude rats
in vivo.
Umbilical cord blood EPCs transplanted via tail vein into
nude mice, they incorporated into capillary networks in ische-
mic hind limb and augmented neovascularisation. In addition,
in ischemic tissues, there were elevated expressions of VEGF
and stromal-derived factor 1-a, both of which had chemotactic
effect on EPCs [27].
In our vivo study demonstrated that intramyocardial trans-
plantation of EPCs in canine model of AMI was associated
with neovascularization and improvement of cardiac function.
The localization and homing of transplanted DILDL-UEA-
1human EPCs in canine cardiac tissues were identiﬁed by
detection of these labeled EPCs as ﬂuorescent collected cells
between striated cardiac muscles. The survival of human EPCs
in the transplanted cardiac tissue was observed as positive-
DAPI cells. Immunoﬂuorescence studies done by Silva et al.
[28] identiﬁed that DAPI- and DILDL-UEA-1-positive cells
were localized primarily in the anterolateral wall of cardiac tis-
sue of canine chronic ischemia model. However, in every trans-
planted dog, some lateral and posterior sections showed
labeled cells suggesting migration of transplanted cells.
Our in vivo results suggested that injected EPCs into ische-
mic myocardium improved myocardial function and increased
vascularity. Histopathological cardiac tissue analysis of infarc-
tioned cardiac muscle transplanted with human EPCs showed
many congested capillaries, congested large blood vessels with
budding & branching, indicating neovascularization in the
area of infarction.
In vivo transplantation of bone marrow-derived cells has
shown regenerated areas of infracted myocardium and new
coronary capillaries formation and this led to limiting func-
tional impairment after myocardial infarction [29]. Transendo-
cardial injection of autologous bone marrowMNCs has shown
increase in myocardial contractility and perfusion in swine
[30]. In vitro study showed evidence of bone marrow stem cells
differentiation into cardiomyocytes, endothelium, and smooth
muscle cells [31]. Autologous bone marrow CD34+ cells trans-
plantation in surgically induced experimental hindlimb ische-
mia revealed cells incorporation into the capillary network
among preserved skeletal myocytes [32]. Comparative Study
between transendocardial (TE) delivery of bone marrow MSCs
after AMI and intracoronary (IC) delivery. The TE group
showed higher cell retention (clusters even in the injury center
of the infarct) with an increased vascularity and greater func-
tional improvement than the IC group (no clusters; cells at
the border of the infarct). The higher local cell density in the
TE group may be important for therapeutic effectiveness
[33]. Human cord blood MNCs transplantation in ischemic
animal models increased the number of capillaries, angiogenic
genes expression and factors [34]. Our ﬁndings suggested that
EPCs express VEGFR-2, which is linked to both neoangiogen-
esis and stem cell homing and migration, also support a contri-
bution of paracrine stimulation of endogenous repair.In our study we detected transplanted EPCs were differen-
tiated into cardiomyocyte-like cells within the ﬁbrotic area of
the infarction and identiﬁed by staining with a speciﬁc cardiac
marker as troponine I. Our results agreed with Badorff et al.
[18] who stated that EPCs from healthy volunteers and CAD
patients can transdifferentiate in vitro into functionally active
cardiomyocytes when cocultivated with rat cardiomyocytes.
According to cell-to-cell contact but not cellular fusion medi-
ates EPC transdifferentiation. Autologous EPCs transplanta-
tion may help cardiomyocyte regeneration in patients with
ischemic heart disease. Koyanagi et al. [35] proved a novel type
of cell-to-cell communication between EPCs and cardiomyo-
cytes in vitro. This communication might enable EPCs through
autocrine action to acquire a cardiomyogenic phenotype with-
out permanent cellular or nuclear fusion.
Silva et al. [28] identiﬁed that transplanted MSCs in a ca-
nine chronic ischemia model were detectable in vessel walls
and were positive for a-smooth muscle actin, suggesting their
transdifferentiation into smooth muscle cells. MSCs were usu-
ally predominant in the luminal face of the endothelium of sev-
eral vessels and expressed factor VIII, highly suggesting their
transdifferentiation into endothelial cells. This transdifferenti-
ation contributed to the signiﬁcantly higher capillary density in
the anterolateral wall of stem cell-treated animals. Tagged hu-
man vascular progenitor cell (VPCs) was injected in immuno-
suppressed dogs proximal to created critical stenosis. VPCs are
self-renewing, can differentiate predominantly into ECs, SMCs
and partly into cardiomyocytes. One month later, there was an
increase in coronary blood ﬂow (CBF) distal to the stenotic ar-
tery, resulting in functional improvement of the ischemic myo-
cardium [36]. Murasawa et al. [37] evaluated nich-dependent
expression proﬁle of EPCs in vitro. Coculture of human EPCs
with rat cardiac myoblast cell lineage (H9C2) revealed that
EPCs can contribute not only to vasculogenesis but also to
myogenesis in ischemic myocardium in vivo.
To detect homing, localization of transplanted EPCs and
their role of in cardiac repair, gene expression of human VEG-
FR-2 gene and human eNOS gene were measured by Real-
time qPCR on infarctioned tissues & on adjacent infarct tissues
in group 1; EPCs-AMI treated canines. Quantitative gene
expression of both human VEGFR-2 and human eNOS genes
showed high signiﬁcant difference between expressions on
infarctioned tissues compared to expressions on adjacent in-
farct tissues. Human VEGFR-2 and eNOS genes expression
was not expressed by QRT-PCR in group 2 canine heart tis-
sues as they were not injected with human EPCs. Our results
were supported by Tei et al. [38] who transplanted peripheral
mobilized human granulocyte colony-stimulating CD34+ with
atelocollagen to injured medial collateral ligament in immuno-
deﬁcient rats. RT-PCR and immunohistochemical staining at
the injury site demonstrated that molecular and histological
expression of human-speciﬁc markers for endothelial cells such
as human VEGF was increased in transplanted CD34+ group
compared with the other groups transplanted with MNCs at
one week.Conclusions
The intracardiac administration of EPCs enhances neovascu-
larisation after induced experimental AMI. Therefore, EPCs
might be useful for cell therapy as potentially promote both
Human EPCs and angiogenesis 143neovascularization and cardiac regeneration in ischemic heart
disease. In conclusion, EPCs can be isolated from the human
umbilical cord blood and transdifferentiated into cardiomyo-
cyte like cells in AMI experimental model. Large-scale studies
should be induced to examine the potential effects of this novel
approach on the risk of death and complications in patients
with large acute myocardial infarctions and depressed left ven-
tricular contractile function.
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